PMID- 37615697
OWN - NLM
STAT- MEDLINE
DCOM- 20240124
LR  - 20240201
IS  - 1435-702X (Electronic)
IS  - 0721-832X (Print)
IS  - 0721-832X (Linking)
VI  - 262
IP  - 1
DP  - 2024 Jan
TI  - MERCURY-3: a randomized comparison of netarsudil/latanoprost and 
      bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
PG  - 179-190
LID - 10.1007/s00417-023-06192-0 [doi]
AB  - PURPOSE   : To compare the efficacy and safety of the fixed-dose combination 
      (FDC) of netarsudil 0.02%/latanoprost 0.005% ophthalmic solution (NET/LAT; 
      Roclanda((R))) with bimatoprost 0.03%/timolol maleate 0.5% (BIM/TIM; Ganfort((R))) 
      ophthalmic solution in the treatment of open-angle glaucoma (OAG) and ocular 
      hypertension (OHT). METHODS: MERCURY-3 was a 6-month prospective, double-masked, 
      randomized, multicenter, active-controlled, parallel-group, non-inferiority 
      study. Patients (>/= 18 years) with a diagnosis of OAG or OHT in both eyes that was 
      insufficiently controlled with topical medication (IOP >/= 17 mmHg in >/= 1 eye 
      and < 28 mmHg in both eyes) were included. Following washout, patients were 
      randomized to once-daily NET/LAT or BIM/TIM for up to 6 months; efficacy was 
      assessed at Week 2, Week 4, and Month 3; safety was evaluated for 6 months. 
      Comparison of NET/LAT relative to BIM/TIM for mean IOP at 08:00, 10:00, and 
      16:00 h was assessed at Week 2, Week 6, and Month 3. Non-inferiority of NET/LAT 
      to BIM/TIM was defined as a difference of </= 1.5 mmHg at all nine time points 
      through Month 3 and </= 1.0 mmHg at five or more of nine time points through Month 
      3. RESULTS: Overall, 430 patients were randomized (NET/LAT, n = 218; BIM/TIM, 
      n = 212), and all received at least one dose of study medication. Efficacy 
      analyses were performed at Month 3 on 388 patients (NET/LAT, n = 184; BIM/TIM, 
      n = 204). NET/LAT demonstrated non-inferiority to BIM/TIM, with a 
      between-treatment difference in IOP of </= 1.5 mmHg achieved at all time points 
      and </= 1.0 mmHg at the majority of time points (six of nine) through Month 3. Mean 
      diurnal IOP during the study ranged from 15.4 to 15.6 mmHg and 15.2 to 15.6 mmHg 
      in the NET/LAT and BIM/TIM groups respectively, with no between-group 
      statistically significant difference. No significant differences were observed in 
      key secondary endpoints. No serious, treatment-related adverse events (AEs) were 
      observed, and AEs were typically mild/moderate in severity. The most common 
      treatment-related AEs were conjunctival hyperemia (NET/LAT, 30.7%; BIM/TIM, 9.0%) 
      and cornea verticillata (NET/LAT, 11.0%; BIM/TIM, 0%). CONCLUSIONS: Once-daily 
      NET/LAT was non-inferior to BIM/TIM in IOP reduction in OAG and OHT, with AEs 
      consistent with previous findings. NET/LAT offers a compelling alternative FDC 
      treatment option for OAG and OHT.
CI  - (c) 2023. The Author(s).
FAU - Stalmans, Ingeborg
AU  - Stalmans I
AUID- ORCID: 0000-0001-7507-4512
AD  - Department of Ophthalmology, University Hospitals UZ Leuven, Louvain, Belgium. 
      ingeborg.stalmans@mac.com.
AD  - Research Group of Ophthalmology, Department of Neurosciences, Catholic University 
      KU Leuven, Louvain, Belgium. ingeborg.stalmans@mac.com.
FAU - Lim, Kin Sheng
AU  - Lim KS
AD  - KCL Frost Eye Research Department, St Thomas' Hospital, London, UK.
FAU - Oddone, Francesco
AU  - Oddone F
AD  - IRCCS Fondazione Bietti, Rome, Italy.
FAU - Fichtl, Marek
AU  - Fichtl M
AD  - Department of Ophthalmology, First Faculty of Medicine, Charles University and 
      General University Hospital in Prague, Prague, Czech Republic.
AD  - Department of Ophthalmology for Children and Adults, Second Faculty of Medicine, 
      Charles University and University Hospital Motol in Prague, Prague, Czech 
      Republic.
FAU - Belda, Jose I
AU  - Belda JI
AD  - Department of Ophthalmology, Hospital Universitario de Torrevieja, Alicante, 
      Spain.
AD  - Visionker Eye Clinic, Torrevieja, Spain.
FAU - Hommer, Anton
AU  - Hommer A
AD  - Private Office for Ophthalmology and Optometry, Albertgasse 39/10, 1080, Vienna, 
      Austria.
FAU - Laganovska, Guna
AU  - Laganovska G
AD  - Riga Stradins University, P.Stradins Clinical University Hospital, Riga, Latvia.
FAU - Schweitzer, Cedric
AU  - Schweitzer C
AD  - CHU Bordeaux, Department of Ophthalmology, 33000, Bordeaux, France.
AD  - Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Team LEHA, 
      UMR 1219, 33000, Bordeaux, France.
FAU - Voykov, Bogomil
AU  - Voykov B
AD  - Centre for Ophthalmology, University Hospital Tuebingen, Tuebingen, Germany.
FAU - Zarnowski, Tomasz
AU  - Zarnowski T
AD  - Department of Diagnostics and Microsurgery of Glaucoma, Medical University, 
      Lublin, Poland.
FAU - Hollo, Gabor
AU  - Hollo G
AUID- ORCID: 0000-0002-0904-4849
AD  - Tutkimusz Ltd, Solymar, Hungary.
AD  - Eye Center, Prima Medica Health Centers, Budapest, Hungary.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20230824
PL  - Germany
TA  - Graefes Arch Clin Exp Ophthalmol
JT  - Graefe's archive for clinical and experimental ophthalmology = Albrecht von 
      Graefes Archiv fur klinische und experimentelle Ophthalmologie
JID - 8205248
RN  - 817W3C6175 (Timolol)
RN  - QXS94885MZ (Bimatoprost)
RN  - 6Z5B6HVF6O (Latanoprost)
RN  - W6I5QDT7QI (netarsudil)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Ophthalmic Solutions)
RN  - 0 (Benzoates)
RN  - 11P2JDE17B (beta-Alanine)
SB  - IM
MH  - Humans
MH  - *Glaucoma, Open-Angle/diagnosis/drug therapy
MH  - Timolol/adverse effects
MH  - Bimatoprost/therapeutic use
MH  - Latanoprost/adverse effects
MH  - Prospective Studies
MH  - Intraocular Pressure
MH  - Antihypertensive Agents/adverse effects
MH  - Tonometry, Ocular
MH  - *Ocular Hypertension/diagnosis/drug therapy
MH  - Ophthalmic Solutions
MH  - Treatment Outcome
MH  - Double-Blind Method
MH  - *Benzoates
MH  - beta-Alanine/*analogs & derivatives
PMC - PMC10806046
OTO - NOTNLM
OT  - Bimatoprost/timolol
OT  - Glaucoma
OT  - Intraocular pressure
OT  - Netarsudil/latanoprost
OT  - Rho-kinase inhibitor
COIS- IS reports financial support from Aerie Pharmaceuticals Ireland Ltd during the 
      conduct of this study; and grants and personal fees from Thea and Santen, 
      personal fees from Eye-D Pharma, Allergan-Abbvie, Horus and Alcon, and is 
      a co-founder and shareholder of, and consultant for, MONA, outside the submitted 
      work. KSL reports grants and lecture fees from Santen during the conduct of the 
      study. FO reports grants and personal fees from Santen and Abbvie outside the 
      submitted work. MF reports personal fees and non-financial support from Santen 
      outside the submitted work. JIB reports personal fees from Glaukos, Zeiss and 
      Santen, and personal fees and non-financial support from Esteve, outside the 
      submitted work. AH reports personal fees from Aerie Pharmaceuticals Ireland 
      Ltd during the conduct of this study, and personal fees from Thea and Santen 
      outside the submitted work. GL has nothing to disclose. CS reports personal fees 
      from Abbvie, Horus, Glaukos, Thea, Alcon, Santen, Nicox and Johnson & Johnson 
      outside the submitted work. BV reports grants from Aerie Pharmaceuticals Ireland 
      Ltd during the conduct of this study and grants from Santen outside the submitted 
      work. TZ has nothing to disclose. GH reports personal fees from Santen outside 
      the submitted work.
EDAT- 2023/08/24 13:43
MHDA- 2024/01/24 06:43
PMCR- 2023/08/24
CRDT- 2023/08/24 11:05
PHST- 2023/03/25 00:00 [received]
PHST- 2023/07/23 00:00 [accepted]
PHST- 2023/06/22 00:00 [revised]
PHST- 2024/01/24 06:43 [medline]
PHST- 2023/08/24 13:43 [pubmed]
PHST- 2023/08/24 11:05 [entrez]
PHST- 2023/08/24 00:00 [pmc-release]
AID - 10.1007/s00417-023-06192-0 [pii]
AID - 6192 [pii]
AID - 10.1007/s00417-023-06192-0 [doi]
PST - ppublish
SO  - Graefes Arch Clin Exp Ophthalmol. 2024 Jan;262(1):179-190. doi: 
      10.1007/s00417-023-06192-0. Epub 2023 Aug 24.